Slide 1: Oculus Innovative Sciences
OCULUS | Innpyaliyesciences
Slide 2: Safe Harbor Statement
The Safe Harbor Statement Under the Private Securities Litigation Reform Act of 1995 This presentation includes forward - looking statements that are made pursuant to the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995 . While these statements are made to convey to t
Slide 3: Era of Antibiotics - Penicillin
Era of Antibiotics - Penicillin Fleming 1928 Florey & Chain 1940
Slide 4: Surgeon General 1967 quote on infectious diseases
“ The time has come to close the book on infectious diseases. We have basically wiped out infection in the United States. ” William Stewart, U.S. Surgeon General, 1967
Slide 5: Antibiotics: Dates of Discovery
Antibiotics: Dates of Discovery
Slide 6: U.S. Antimicrobial Use
U.S. Antimicrobial Use U.S. Antimicrobial Use lock BB Nontherapeutic use - Liv [Bl Therapeutic use - Livestock LI Therapeutic use - Humans Bi Other (soaps, pesticides, pets, etc OCULUS Innovative Sciences
Slide 7: Growing resistance to antibiotics as a threat
“The danger posed by growing resistance to antibiotics should be ranked along with terrorism on a list of threats to the nation.” UK’s Chief M edical O fficer, Professor Dame Sally Davies Mar 2013
Slide 8: Studying Microbes in Frozen Tundra
Studying Microbes in Frozen Tundra
Slide 9: Human Immune System
Human Immune System OCULUS
Slide 10: Neutrophil Mode of Action
Neutrophil Mode of Action
Slide 11: The Breakthrough – Non-Antibiotic Antimicrobial
The Breakthrough – Non - Antibiotic Antimicrobial Kills broad spectrum of: • bacteria , viruses, spores and fungi • antibiotic - resistant strains (MRSA, VRE) 4 million patients without any significant adverse events Proven efficacy in over 30 studies, including randomized/controlled Phase II FDA st
Slide 12: Dr. Adam Landsman testimonial
Dr. Adam Landsman Assistant Professor Harvard Medical School “Microcyn is one of the few topicals that’s effective for patients that are affected with MRSA ...”
Slide 13: Dr. Tom Wolvos testimonial
Dr. Tom Wolvos Chief of General Surgery Scottsdale Healthcare Scottsdale, Arizona Editor of the Scottsdale Wound Management Guide “Microcyn seems to decrease inflammation ... I changed to Microcyn gel and saw not only healing of the wound, but a dramatic decrease in the inflammatory reaction that my
Slide 14: Acute Care/Hospital Products
Acute Care/Hospital Products U.S. Partner : Eloquest Healthcare® is focused specifically on serving hospitals, their healthcare practitioners, and patients. Eloquest Healthcare® provides value within the acute care market by helping to improve patient outcomes.
Slide 15: Dermatology Products
Dermatology Products U.S. Partner: Quinnova Pharmaceuticals is a specialty pharmaceutical company founded on innovative, patent - protected dermal delivery technologies
Slide 16: Dr. Rebecca Smith testimonial
Dr. Rebecca Smith “I see a lot of colonization of MRSA. I see kids with chronic atopic dermatitis who end up with the infection over again and again and again. And they’re often colonized in their nose, so I can take the solution or the gel even and have them apply in their noses a couple of times a
Slide 17: Animal Healthcare Products
Animal Healthcare Products Partner: Innovacyn Inc. is a privately held company that provides premier human and animal healthcare products based on advanced scientific research
Slide 18: Vetericyn endorsement and Ruthigen New Drug Timeline
Cesar Millan The Dog Whisperer “Vetericyn will help your dog heal faster from a wound or infection. That means fewer costly and stressful visits to the vet .” “Vetericyn is great to use on hot spots, rashes and skin irritations . It is safe as water and contains no steroids, antibiotics, alcohol or
Slide 19: Approved March 2010
APPROVED —> MAR 2 8 2010 * OCULUS Innovative Sinses
Slide 20: Summary Income Statement
Summary Income Statement | Three Months Ended December 31, 20122011 Revenues Product $3357 $2507 Service 183193 Total revenues 73540" 2,790 Cost of revenues Product 6757 Service 163184 Total cost ofrevenues "1,069" 938 Gross profit 2aT| 1882 (Operating expenses Research and developmen 509609 Seling,
Slide 21: Breakeven Analysis
Breakeven Analysis *Dollars in million ** Breakeven and growth is after separation of Ruthigen and without their expenses
Slide 22: Current Revenue Sources
Current Revenue Sources Partners Approvals SKUs Commercialized Markets Innovacyn FDA 510K 40+ 2009 US/Int’l: Animal health AmDerma FDA 510K 3 2012 US: Derm Rx Eloquest FDA 510K 7 2012 US : Acute care More Pharma MOH Drug 4 2005 Mexico: Pharmacy, hospital, derm Alkem Drug 3 India: Hospital and pharma
Slide 23: Key Facts
Key Facts Closing Stock Price 52 - week Range $2.66 - $8.47 Shares Outstanding 5.3M Options/Warrants Outstanding 2.5M Market Capitalization $20.7M Average Daily Volume (52 week) 12,000 Trailing Revenue (12 months ending 12/31/12) $15.5M Net Loss minus non - cash expenses (3 months ending 12/31/12) $
Slide 24: Intellectual Property
Intellectual Property 35 Issued Patents • 5 issued US • 12 issued EU • 18 issued International Pending Applications • 109 U.S. and foreign Claims Covering: • Chemical composition • Apparatus • Method of manufacturing • Therapeutic uses IP ruled enforceable by U.S. Federal Court in 2009
Slide 25: Preliminary Scar Data
Preliminary Scar Data % Improvement of Microcyn over Market Leader: (based on % reduction from base line) Investigator Global Assessment: Microcyn Market Leader % Very good/ good at Day 84 55% 38% Percentage Microcyn Leader DifferenceImprovement P values Vascularity -42% -28% -14% 50% 25% Pliability
Slide 26: De-Risked Company
“De - Risked Company” Microcyn Technology marketed in more than 20 countries Last three years => average revenue growth = 35% Robust product pipeline in US, Europe, Mexico/Latin America, Middle East and Asia Expanding global footprint Ruthigen = > internally used antimicrobial drug focused on preven
Slide 27: More Information
More Information Jim Schutz , Oculus CEO jschutz@oculusis.com Bob Miller , Oculus CFO bmiller@oculusis.com Dan McFadden , Oculus VP of IR/PR dmcfadden@ oculusis.com Oculus Innovative Sciences 1129 North McDowell Blvd. Petaluma, California 94954 Telephone: +1 (707) 283 - 0550 www.oculusis.com Nasdaq